Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice. The gene discussed is IL2; the disease is pancreatic ductal adenocarcinoma.